A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination with Carboplatin or Cisplatin + Pemetrexed Compared with Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer

This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have Stage IV non-squamous NSCLC. Eligible participants will be randomized by a 1:1 ratio into 2 groups: Arm A (atezolizumab + carboplatin or cisplatin + pemetrexed) and Arm B (carboplatin or cisplatin + pemetrexed). The study will be conducted in two phases: Induction Phase and Maintenance Phase.

Inclusion Criteria:
•Histologically or cytologically confirmed, Stage IV non-squamous NSCLC without any prior treatment
•Tumor PD-L1 expression as determined by immunohistochemistry (IHC) assay of archival tumor tissue or tissue obtained at screening
Phase III
Rachel Sanborn, M.D.
Brenda Fisher
  • Oncology and Hematology Care Eastside
  • Oncology and Hematology Care Westside